Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Purple Biotech American Depositary Shares Representing 200 Ord Shs PPBT

Healthcare
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi... see more

Recent & Breaking News (NDAQ:PPBT)

Purple Biotech to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 3, 2021

Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219

GlobeNewswire October 26, 2021

Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance

GlobeNewswire October 22, 2021

Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update

GlobeNewswire September 13, 2021

Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results

GlobeNewswire August 5, 2021

Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting

GlobeNewswire June 4, 2021

Purple Biotech to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 26, 2021

Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting

GlobeNewswire May 20, 2021

Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors

GlobeNewswire May 19, 2021

Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients

GlobeNewswire April 23, 2021

Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting

GlobeNewswire April 13, 2021

Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers

GlobeNewswire March 19, 2021

Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting

GlobeNewswire March 11, 2021

Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors

GlobeNewswire March 3, 2021

Purple Biotech Provides Corporate Update and Reports Second Half and Full Year 2020 Financial Results

GlobeNewswire March 2, 2021

Purple Biotech to Present at the B. Riley Oncology Investor Conference

GlobeNewswire January 18, 2021

Purple Biotech to Ring the Nasdaq Stock Market Opening Bell

GlobeNewswire January 4, 2021

Kitov Announces Name Change to Purple Biotech Ltd.

GlobeNewswire December 10, 2020

Kitov Pharma to Participate in November Investor Conferences

GlobeNewswire November 11, 2020

Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb

GlobeNewswire November 9, 2020